SecBot SecBot
6-K ·Filed Jul 29, 2026

RDY

DR REDDYS LABORATORIES LTD
NEUTRAL
Impact 4/10
Horizonweeks Processed3mo ago SEC0001575872-26-000538
Actionable Insight • Neutral

Monitor Dr. Reddy's response to the USFDA regarding the three Form 483 observations and any subsequent regulatory actions (e.g., warning letter, import alert) that could affect the Srikakulam facility's output or pending product approvals. The inspection was a PAI, so resolution is key for the associated product's launch timeline.

DirectionNeutral
Confidencehigh
Horizonweeks

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$11.76
T+0 close · Jul 29, 2026 · via day close
Latest settled
+12.50%
T+60 · $13.23
Vs SPY
+7.77%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 29 $11.76entry
  2. T+1 · 4mo ago +0.60%α −1.08% · $11.83
  3. T+5 · 3mo ago +3.23%α −2.30% · $12.14
  4. T+20 · 3mo ago +3.91%α −1.11% · $12.22
  5. T+60 · 26d ago +12.50%α +7.77% · $13.23
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Dr. Reddy's disclosed that the USFDA completed a 10-day Pre-Approval Inspection (PAI) and GMP inspection at its FTO-SEZ Process Unit-02 in Srikakulam, Andhra Pradesh, from July 20-29, 2026. The company received a Form 483 with three observations, which it will address within the stipulated timeline. This is a routine regulatory event with no material financial impact disclosed, but the three observations introduce minor regulatory risk for the facility's compliance status and potential product approvals tied to the PAI.

Key Facts

  • USFDA completed a Pre-Approval Inspection (PAI) and GMP inspection at Dr. Reddy's FTO-SEZ Process Unit-02 in Srikakulam, Andhra Pradesh from July 20 to July 29, 2026.
  • The company received a Form 483 with three observations, which it will address within the stipulated timeline.
  • No financial figures, revenue impact, or material operational disruptions were disclosed in the filing.

Financial Impact

No financial impact disclosed; three Form 483 observations are routine and typically resolved without material cost.

Risk Factors

  • Failure to adequately address the three Form 483 observations could lead to escalated FDA enforcement actions, including warning letters or import alerts.
  • The PAI outcome may delay or block approval of the product(s) tied to the inspection, impacting future revenue expectations.

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
52% bullish (44 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (RDY), Batch item 10001575872-26-000538
Document: 0001575872-26-000538-index.html0001575872-26-000538
Document: 0001575872-26-000538.txt0001575872-26-000538
6-K Filing (RDY), Batch item 40001575872-26-000538
Document: 0001575872-26-000538-index.html0001575872-26-000538
Document: 0001575872-26-000538.txt0001575872-26-000538

Track record

73 reports on RDY

Performance horizon

7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 12 went positive at some point.

Filters
  1. Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
  2. Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
  3. Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
  4. Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
  5. Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
  6. Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
  7. Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  8. Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
  9. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
  10. Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
Showing 10 of 73

US Market Status

Market Closed · Opens in 5h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 29, 2026